- Home
- CWEN vs PCVX Comparison
CWEN vs PCVX Comparison
Compare CWEN & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWEN
- PCVX
- Stock Information
- Founded
- CWEN 2012
- PCVX 2013
- Country
- CWEN United States
- PCVX United States
- Employees
- CWEN N/A
- PCVX N/A
- Industry
- CWEN Electric Utilities: Central
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- CWEN Utilities
- PCVX Health Care
- Exchange
- CWEN Nasdaq
- PCVX Nasdaq
- Market Cap
- CWEN 3.7B
- PCVX 4.4B
- IPO Year
- CWEN 2013
- PCVX 2020
- Fundamental
- Price
- CWEN $32.41
- PCVX $34.25
- Analyst Decision
- CWEN Strong Buy
- PCVX Strong Buy
- Analyst Count
- CWEN 5
- PCVX 10
- Target Price
- CWEN $36.40
- PCVX $136.50
- AVG Volume (30 Days)
- CWEN 785.7K
- PCVX 1.1M
- Earning Date
- CWEN 08-05-2025
- PCVX 08-05-2025
- Dividend Yield
- CWEN 5.33%
- PCVX N/A
- EPS Growth
- CWEN 20.79
- PCVX N/A
- EPS
- CWEN 0.79
- PCVX N/A
- Revenue
- CWEN $1,406,000,000.00
- PCVX N/A
- Revenue This Year
- CWEN $8.68
- PCVX N/A
- Revenue Next Year
- CWEN $11.21
- PCVX N/A
- P/E Ratio
- CWEN $40.34
- PCVX N/A
- Revenue Growth
- CWEN 9.08
- PCVX N/A
- 52 Week Low
- CWEN $24.40
- PCVX $27.66
- 52 Week High
- CWEN $33.22
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- CWEN 54.28
- PCVX 47.04
- Support Level
- CWEN $31.20
- PCVX $35.46
- Resistance Level
- CWEN $33.22
- PCVX $36.52
- Average True Range (ATR)
- CWEN 0.53
- PCVX 1.42
- MACD
- CWEN -0.09
- PCVX -0.19
- Stochastic Oscillator
- CWEN 53.96
- PCVX 17.62
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.